Recursion Pharmaceuticals is looking to revolutionize the drug development process. The biotech's strategy has yet to deliver major medical breakthroughs. It could soon encounter stiff competition as ...

Evidence that AI-fueled drug discovery is the way forward is hard to find now, but that could change in 2025. After merging with Exscientia, Recursion will have 10 clinical readouts to look forward to ...